1. Home
  2. SCM vs ZBIO Comparison

SCM vs ZBIO Comparison

Compare SCM & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCM
  • ZBIO
  • Stock Information
  • Founded
  • SCM 2012
  • ZBIO 2019
  • Country
  • SCM United States
  • ZBIO United States
  • Employees
  • SCM N/A
  • ZBIO N/A
  • Industry
  • SCM Finance/Investors Services
  • ZBIO
  • Sector
  • SCM Finance
  • ZBIO
  • Exchange
  • SCM Nasdaq
  • ZBIO NYSE
  • Market Cap
  • SCM 387.3M
  • ZBIO 389.2M
  • IPO Year
  • SCM 2012
  • ZBIO 2024
  • Fundamental
  • Price
  • SCM $14.45
  • ZBIO $9.79
  • Analyst Decision
  • SCM Hold
  • ZBIO Strong Buy
  • Analyst Count
  • SCM 1
  • ZBIO 7
  • Target Price
  • SCM $13.00
  • ZBIO $32.29
  • AVG Volume (30 Days)
  • SCM 104.2K
  • ZBIO 220.0K
  • Earning Date
  • SCM 08-06-2025
  • ZBIO 08-16-2025
  • Dividend Yield
  • SCM 11.08%
  • ZBIO N/A
  • EPS Growth
  • SCM 26.74
  • ZBIO N/A
  • EPS
  • SCM 1.42
  • ZBIO N/A
  • Revenue
  • SCM $103,691,042.00
  • ZBIO $15,000,000.00
  • Revenue This Year
  • SCM $0.36
  • ZBIO $206.00
  • Revenue Next Year
  • SCM $2.94
  • ZBIO $41.92
  • P/E Ratio
  • SCM $10.14
  • ZBIO N/A
  • Revenue Growth
  • SCM N/A
  • ZBIO N/A
  • 52 Week Low
  • SCM $11.19
  • ZBIO $5.83
  • 52 Week High
  • SCM $15.56
  • ZBIO $26.25
  • Technical
  • Relative Strength Index (RSI)
  • SCM 72.79
  • ZBIO N/A
  • Support Level
  • SCM $13.87
  • ZBIO N/A
  • Resistance Level
  • SCM $14.50
  • ZBIO N/A
  • Average True Range (ATR)
  • SCM 0.21
  • ZBIO 0.00
  • MACD
  • SCM 0.06
  • ZBIO 0.00
  • Stochastic Oscillator
  • SCM 95.10
  • ZBIO 0.00

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

About ZBIO ZENAS BIOPHARMA INC

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Share on Social Networks: